Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.56	0.67	0.74	0.81	0.85	0.76
Revenue Growth (YoY)	-16.04%	-9.29%	-8.27%	-5.04%	11.80%	-62.45%
Gross Profit	0.56	0.67	0.74	0.81	0.85	0.76
Selling, General & Admin	2.51	3.05	2.96	3.14	-3.85	-2.95
Research & Development	5.61	5.76	5.98	7.76	-9.85	-11.95
Total Operating Expenses	8.11	8.8	8.94	10.91	-13.7	-14.9
Operating Income	8.93	8.13	8.2	10.1	12.84	14.14
Total Non-Operating Income (Expense)	-0.14	-0.25	-0.56	0.08	-0.23	0.3
Pretax Income	8.8	7.88	7.63	10.17	12.62	14.44
Net Income	8.8	7.88	7.63	10.17	10.03	13.73
Net Income Attributable to Preferred Dividends	-	-	-	-	2.59	0.72
Net Income to Common	8.8	7.88	7.63	10.17	10.03	13.73
Net Income Growth	19.37%	3.22%	-24.96%	1.48%	-26.97%	8.74%
Shares Outstanding (Basic)	0	0	0	0	0	0
Shares Outstanding (Diluted)	0	0	0	0	0	0
Shares Change (YoY)	87.11%	70.22%	56.71%	47.49%	54.31%	34.07%
EPS (Basic)	2665.26	-	-9000.00	-9000.00	-27000.00	-36000.00
EPS (Diluted)	2665.26	-	-9000.00	-9000.00	-27000.00	-36000.00
EPS Growth	-36.20%	-	-	-	-	-
Free Cash Flow	-8.36	-7.64	-8.44	-10.81	-9.87	-12.09
Free Cash Flow Per Share	-2530.77	-3160.86	-5943.52	-11926.50	-16059.35	-30356.47
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	1595.36%	1206.23%	1102.96%	1246.42%	1505.51%	1853.08%
Profit Margin	1571.25%	1169.14%	1027.46%	1255.93%	1478.90%	1892.92%
FCF Margin	-1491.96%	-1133.83%	-1136.20%	-1334.57%	-1156.98%	-1584.40%
EBITDA	8.96	8.14	8.21	10.11	12.86	14.15
EBITDA Margin	1600.54%	1207.27%	1104.98%	1248.15%	1507.15%	1854.65%
EBIT	8.93	8.13	8.2	10.1	12.84	14.14
EBIT Margin	1595.36%	1206.23%	1102.96%	1246.42%	1505.51%	1853.08%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q